Inovio's CEO appointed to IVI board of trustees
J. Joseph Kim will serve a three-year term to oversee IVI's governance and management. The IVI operates as an independent international organization that conducts research in more than 20 countries on vaccines against dengue fever, Japanese encephalitis, enteric infections and diarrheal infections. The institute is devoted to developing and introducing vaccines to protect the world's poorest individuals, particularly children in developing countries.
Fred Binka, the project manager for the INDEPTH Malaria Clinical Trials Alliance, and George Siber, the executive chairman of Genocea Biosciences, were also named to the board.
"The new members bring scientific, industrial, and global health expertise that will boost IVI's ability to make an impact in improving the health of the most impoverished," Christian Loucq, the director general of IVI, said. "IVI has undergone several changes to strengthen its governance and management, and to increase transparency. We look forward to capitalizing on the experience and knowledge they bring as we continue to evolve as an institute."
Kim is the founder and CEO of Inovio, where he led the company's focus on developing therapeutic and prophylactic vaccines for developed and developing world markets.
"I am honored to be selected to serve this world class institute," Kim said. "I will bring a sense of urgency to my work with IVI to advance its critical mission for improving human health, especially for impoverished children."